GlyGenix Therapeutics Receives $150,000 Seed Financing Round

  • Feed Type
  • Date
    3/18/2014
  • Company Name
    GlyGenix Therapeutics
  • Mailing Address
    15 Research Drive Woodbridge, CT 06525 USA
  • Company Description
    GlyGenix Therapeutics, Inc. (GTI) is focused on treating and curing Glycogen Storage Diseases (GSDs). Our primary focus is to cure GSD type 1a, which is caused by an inherited gene mutation resulting in altered glycogen metabolism and glucose homeostasis.
  • Website
    http://www.glygenixtherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $150,000
  • Transaction Round
    Seed
  • Proceeds Purposes
    The company will use the funds to continue research and development on its lead drug candidate, AAV-G6Pase, for the treatment of glycogen storage disease type 1a (GSD1a).
  • M&A Terms
  • Venture Investor
    Connecticut Innovations

Trending on Xconomy